Under one in 10 patients who could benefit from obesity jabs including Wegovy are able to get them, caution the global health agency as it releases its inaugural recommendations on the therapies.
Given in excess of 1,000,000,000 people worldwide now living with obesity, it is calling for broader and more equitable availability to these injectable treatments.
According to forecasts, more than two billion will be obese by 2030 unless action is taken.
"The new guidance acknowledges that obesity is a long-term condition that can be treated with thorough and continuous treatment," said WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and distribution challenges are major obstacles to universal availability to the treatments that can assist patients in reducing substantial body mass, notes the organization.
Skinny Jab Scarcity
Despite the current most optimistic case, the manufacturing of such drugs might only reach about 100 million people – under 10% of those who need them, according to the WHO.
The recommendation calls on nations and manufacturers to expand access, by strategies such as voluntary licensing.
The intellectual property rights on the active ingredient – the main component of a leading brand – is scheduled to end in multiple nations in 2026.
How Weight-Loss Drugs Operate
These medications imitate a biological compound to delay gastric emptying, curb appetite and enhance feelings of fullness so people consume fewer calories.
Patients typically begin shedding pounds in the initial weeks of beginning the once-weekly jabs.
Studies indicates users may regain a significant portion within a year of stopping the treatment, because their typical appetite return.
To be overweight or obese elevates your chance for contracting health problems, such as type 2 diabetes, cardiovascular issues, brain attack, and certain cancers.
Excess weight affects people in countries worldwide and was associated with 3.7 million fatalities worldwide in 2024, per the WHO.
